Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

GC Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

GC Biopharma şirketinin toplam hissedar öz sermayesi ₩1,488.1B ve toplam borcu ₩778.4B olup, bu da borç-öz sermaye oranını 52.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₩2,729.5B ve ₩1,241.4B dir. GC Biopharma 'in FAVÖK'ü ₩26.4B faiz karşılama oranı 0.8 dur. Şirketin ₩78.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

52.3%

Borç/özkaynak oranı

₩778.45b

Borç

Faiz karşılama oranı	0.8x
Nakit	₩78.10b
Eşitlik	₩1.49t
Toplam yükümlülükler	₩1.24t
Toplam varlıklar	₩2.73t

Son finansal sağlık güncellemeleri

Recent updates

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Aug 02

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

Jul 12

Is GC Biopharma (KRX:006280) A Risky Investment?

May 25

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: A006280 'nin kısa vadeli varlıkları ( ₩1,168.2B ) kısa vadeli yükümlülüklerini ( ₩754.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: A006280 şirketinin kısa vadeli varlıkları ( ₩1,168.2B ) uzun vadeli yükümlülüklerini ( ₩487.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: A006280 'nin net borç/öz sermaye oranı ( 47.1% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: A006280 şirketinin borç/öz sermaye oranı son 5 yılda 35.6% seviyesinden 52.3% seviyesine yükseldi.

Borç Kapsamı: A006280 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: A006280 'in borcuna ilişkin faiz ödemeleri EBIT ( 0.8 x kapsam) tarafından iyi karşılanmıyor.

GC Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is GC Biopharma (KRX:006280) A Risky Investment?

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Recent updates

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

New 90-day high: ₩505,000

GC Pharma and Clinigen K.K. Announces Marketing Approval for Hunterase ICV Injection 15 mg

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

New 90-day high: ₩475,000

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Upcoming Dividend of ₩1,000 Per Share

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Analysts update estimates

New 90-day high: ₩378,000

Analysts update estimates

Price target raised to ₩198,111

Grifols, S.A. (BME:GRF) completed the acquisition of Plasma Fractionation Facility in Montreal and Plasma Collection Centers in US from Green Cross Corporation (KOSE:A006280).

New 90-day high - ₩239,000

Price target raised to ₩168,250

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi